Influenza Vaccination, ACEI and ARB in the Evolution of COVID-19

A study to determine if influenza vaccination or ACEI or ARB medication has effects on COVID-19

Have you had COVID-19? Are you vaccinated against the influenza, or taking ACEI or ARB medication? Contact the PI by clicking the button below.

What do you know about ACEI and ARB?

Angiotensin-converting-enzyme inhibitors (ACEI) and Angiotensin II Receptor blockers (ARB) are medicines to lower blood pressure and for the treatment of heart failure.

Description of the Study:

  • Title: Evaluation of Influenza Vaccination and Treatment With ACEI and ARB in the Evolution of SARS-Covid19 Infection.
  • Principal Investigator: Anna Puigdellívol-Sánchez.
  • Center of Implementation: Consorci Sanitari de Terrassa.
  • Study Population: 2574 patients admitted in the Hospital of Terrassa from March 1, 2020, with any of the following conditions: COVID-19, Influenza Vaccination, ACE inhibitor or Angiotensin II receptor antagonist.
  • Study Type: Observational Clinical Trial.
  • Design:
    – If patients treated with ACE inhibitor evolve positively, this treatment would be added in a random selection of new admitted patients suffering COVID-19, and results would be compared to a control group of admitted patients.
    – If patients treated with ARB evolve positively, this treatment would be added in a random selection of new admitted patients suffering COVID-19, and results would be compared to a control group of admitted patients.

Objectives of the Study:

Principal Objective: The primary objective is to evaluate whether the admitted patients who have previously received the influenza vaccine or treated with ACEI or ARB show a better evolution.
To study the number of patients admitted at the hospital, their comorbidity (Charlson index), the number of previous treatments, the length of admission, the need or not of the Intensive Care Unit (ICU) and their final status (survivors or non survivors).

More about this Study:

Scientific Context: Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection.

The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving treatment show a better evolution.

Consorci Sanitari de Terrassa: The CST is an integrated healthcare organisation with a public service vocation, which is a consortium of the Autonomous Government of Catalonia, Terrassa City Council and the San Lázaro Foundation.

The CST centres have more than 2,000 professionals who provide highly qualified health and social care to a reference population of more than 160,000 inhabitants.

Jordi Gol I Gurina Foundation

Other Studies about Pharmacology:

E-speranza-COVID19 Project

This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.


CIBERES UCI COVID is a fundamental study that will improve care of critical patients infected by COVID-19.

ANTICOV Study : COVID-19 en Afrique

Collaborez avec l’étude ANTICOV et contribuez à traiter la COVID-19 en Afrique.

Antibiotic prescription during the COVID-19 pandemic

Antimicrobial stewardship approaches urgently need to be reinforced during the COVID-19 pandemic. This study evaluates the impact of the COVID-19 on antibiotic consumption.

Progestérone pour traiter le COVID-19

Est-ce que les hormones sexuelles peuvent aider les hommes survivre le COVID-19 ? Cette étude a pour objectif évaluer la sécurité et l’efficacité de la…

PanCOVID19: Evaluating Pharmacological Treatments

Open, randomized, adaptive, phase III clinical trial study to evaluate the efficacy of various pharmacological alternatives in the treatment of severe infection in COVID-19 pediatric…

MMR Vaccine and the Immune Response to SARS-CoV-2

Is the MMR vaccine involved in the immune response to SARS-CoV-2? This study aims to answer that question by investigating the effect of the MMR…

AstraZeneca Study of COVID-19 Vaccine Candidate AZD1222

Clinical trial designed to determine if the vaccine candidate, AZD1222, can prevent symptomatic COVID-19.

Amantadine and COVID-19

Participate in this study and help us discover the role of Amantadine as a therapeutic alternative to fight COVID-19.

Break the COVID-19 Chain #BreaktheChainBCN

Prevention is as important as treatment in a pandemic.